Cerebral venous sinus thrombosis 7–28 days post #COVIDVaccination (AstraZeneca):

 4 VITT cases (women aged 41–46 years) from a single tertiary referral centre in London, UK, who suffered cerebral venous sinus thrombosis with or without thrombosis elsewhere 7–28 days post #COVIDVaccination (AstraZeneca):

Clinical and biological features of cerebral venous sinus thrombosis following ChAdOx1 nCov-19 vaccination

We report our experience of four VITT cases from a single tertiary referral centre in London, UK, who suffered cerebral venous sinus thrombosis (CVST) with or without thrombosis elsewhere. Baseline clinical and laboratory features are shown in table 1. Informed written consent was obtained from all patients before publication. All patients fulfilled the proposed diagnostic criteria for VITT3 4. Each case was reportedvia the MHRA Yellow card scheme and other national VITT–CVST surveillance projects.

To our knowledge, this is the first study to interrogate immune, coagulant/haemostatic, platelet and endothelial disturbances combined with imaging in VITT. Our clinical and laboratory findings are remarkably uniform, consistent with a genuine syndrome3 4 and the good outcomes reported here suggest that rapid agressive therapy directed at pathogenesis could be beneficial. As the number of VITT cases rises globally, it is of utmost importance to understand the biological mechanisms that drive or further complicate VITT.

CONTINUE HERE:

https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.long